The Italian specialty pharmaceutical company, Cosmo Pharmaceuticals SpA, expects to be profitable again in 2009 on increased sales of its lead product for the treatment of ulcerative colitis, Lialda/Mezavant (mesalazine). ---Subscribe to MedNous to access this article--- Company News
